Kiora Pharmaceuticals Inc
7EY
Company Profile
Business description
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Contact
332 Encinitas Boulevard
Suite 102
EncinitasCA92024
USAT: +1 858 224-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
12
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,231.50 | 66.90 | -0.72% |
| CAC 40 | 8,216.58 | 22.60 | -0.27% |
| DAX 40 | 24,278.63 | 30.15 | -0.12% |
| Dow JONES (US) | 47,706.37 | 161.78 | 0.34% |
| FTSE 100 | 9,696.74 | 42.92 | 0.44% |
| HKSE | 26,346.14 | 87.56 | -0.33% |
| NASDAQ | 23,827.49 | 190.04 | 0.80% |
| Nikkei 225 | 51,235.52 | 1,016.34 | 2.02% |
| NZX 50 Index | 13,427.07 | 24.41 | 0.18% |
| S&P 500 | 6,890.89 | 15.73 | 0.23% |
| S&P/ASX 200 | 8,941.40 | 70.70 | -0.78% |
| SSE Composite Index | 3,988.22 | 8.72 | -0.22% |